Clinical trial
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute…
NCT00154349 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00154349 |
|---|---|
| Title | Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia |
| Official title | Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate |
| Enrollment | 8 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: